Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Fertility preservation options in breast cancer patients. (CROSBI ID 226553)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kasum, Miro ; von Wolf, M ; Franulić, D ; Čehić, E ; Klepac-Pulanić, Tajana ; Orešković, Slavko ; Juras, Josip Fertility preservation options in breast cancer patients. // Gynecological endocrinology, 31 (2015), 11; 846-851. doi: 10.3109/09513590.2015.1081684.

Podaci o odgovornosti

Kasum, Miro ; von Wolf, M ; Franulić, D ; Čehić, E ; Klepac-Pulanić, Tajana ; Orešković, Slavko ; Juras, Josip

engleski

Fertility preservation options in breast cancer patients.

The purpose of this review is to analyse current options for fertility preservation in young women with breast cancer (BC). Considering an increasing number of BC survivors, owing to improvements in cancer treatment and delaying of childbearing, fertility preservation appears to be an important issue. Current fertility preservation options in BC survivors range from well- established standard techniques to experimental or investigational interventions. Among the standard options, random-start ovarian stimulation protocol represents a new technique, which significantly decreases the total time of the in vitro fertilisation cycle. However, in patients with oestrogen-sensitive tumours, stimulation protocols using aromatase inhibitors are currently preferred over tamoxifen regimens. Cryopreservation of embryos and oocytes are nowadays deemed the most successful techniques for fertility preservation in BC patients. GnRH agonists during chemotherapy represent an experimental method for fertility preservation due to conflicting long-term outcome results regarding its safety and efficacy. Cryopreservation of ovarian tissue, in vitro maturation of immature oocytes and other strategies are considered experimental and should only be offered within the context of a clinical trial. An early pretreatment referral to reproductive endocrinologists and oncologists should be suggested to young BC women at risk of infertility, concerning the risks and benefits of fertility preservation options.

Breast cancer ; chemotherapy ; fertility preservation options ; young age

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

31 (11)

2015.

846-851

objavljeno

0951-3590

10.3109/09513590.2015.1081684.

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost